Land: Storbritannien
Sprog: engelsk
Kilde: VMD (Veterinary Medicines Directorate)
Enrofloxacin
Bayer plc
QJ01MA90
Enrofloxacin
Solution for injection
POM-V - Prescription Only Medicine – Veterinarian
Cattle
Antimicrobial
Expired
1999-06-14
Revised: November 2011 AN: 01356/2011 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Baytril ® Max 100 mg/ml Solution for Injection for Cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE CONSTITUENTS MG PER ML Enrofloxacin 100 RELEVANT CONSTITUENTS OF THE EXCIPIENTS Benzyl alcohol 20 n-butyl alcohol 30 For full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Solution for injection. Clear yellow sterile aqueous solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Indicated for the treatment of bovine respiratory disease associated with _Mannheimia haemolytica,_ _Pasteurella multocida, Haemophilus somnus_ and _Mycoplasma_ spp. where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice. Indicated for the treatment of local signs (inflammation, milk quality and yield) associated with peracute/acute mastitis in lactating dairy cattle caused by E. coli, where herd history and previous sensitivity testing indicate enrofloxacin as the drug of choice. Revised: November 2011 AN: 01356/2011 Page 2 of 6 4.3 CONTRAINDICATIONS Baytril Max should not be used for prophylaxis 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE i. Special precautions for use in animals Normal sterile precautions should be taken. The safety of the product has not been established in calves when administered by the intravenous route and use of this route of administration in calves is therefore not recommended. Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instruct Læs hele dokumentet